“Secukinumab Treatment in Patients With Spondyloarthritis and Concomitant Demyelinating Disease: Rationale of IL-17 Inhibition and Clinical Outcome”. 2022. Archives of Clinical and Medical Case Reports 6 (5): 660-68. https://fortunejournals.org/ojs/index.php/acmcr/article/view/22670.